Knowledge Exchange by ISID

JOIN WEBINAR
About this activity
References
Discussion Forum (0)
Rate & Comment (0)
Dengue Vaccines: Directions for the Future
This webinar will be hosted on Thursday, the 8th of December 2022 at 08:00 - 09:00 am EST.

​If you are unable to attend the live event, bookmark this link! An on-demand version will be available within 2 to 3 hours.

Chairs:
  • Finghani Mphande-Nyasulu
  • Tatiana Pinto

Speakers:
  • Anon Srikiatkhachorn
  • Cristina Barroso Hofer

According to the WHO, the incidence of dengue has increased considerably in recent decades. Dengue is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. Asia bears about 70% of the global burden of dengue. There is no specific treatment for dengue. So far only one dengue vaccine CYD-TDV has been licensed for use. It is currently in use in about 20 countries globally. There are several candidate vaccines in different stages of development, some are currently in various stages of Clinical Trials. Several challenges have been faced in the development of the vaccines, some of which include the nature of the virus itself that has four serotypes and the immune response to the vaccine.
 
Technical Settings
This Live Session is available on all latest browsers. For the best viewing experience, a high-speed internet connection is required.
If you have a problem getting access to the live webinar, please contact the technical crew at support@multilearning.com.
1. Amorim, Jaime Henrique et al. Dengue vaccines: where are we now and where we are going? The Lancet Infectious Diseases 2022. Volume 22, Issue 6, 756 – 757
2. Pinheiro-Michelsen JR, Souza SO, Santana IVR et al. Anti-dengue vaccines: from development to clinical trials. Front Immunol. 2020; 111252
3. Rose, Anuradha et al. Bioethics of establishing a CHIM model for dengue vaccine development. International Journal of Infectious Diseases 2019. Volume 84, S74 - S79
4. King, C.-C. Public health needs and challenges in influenza and dengue vaccines–Implications from epidemiological findings. International Journal of Infectious Diseases 2020 Volume 101, 324
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies